Inova Labs receives CE Mark Approval for the LifeChoice® Portable Oxygen Concentrator System - Gilde Healthcare

Inova Labs receives CE Mark Approval for the LifeChoice® Portable Oxygen Concentrator System

1. Dezember 2011

New Technology enables COPD patients to experience true portability while maintaining appropriate oxygen concentration levels during both day and night

Austin, TX – Inova Labs, a privately held medical device company focused on developing innovative products for the Chronic Obstructive Pulmonary Disease (COPD) Market, announced today that it has received CE Mark approval to begin marketing the LifeChoice® Portable Oxygen Concentrator System in Europe.

“This is a major milestone for our Company and for COPD patients who are on Long Term Oxygen Therapy,” said John Rush, CEO of Inova Labs.   “The LifeChoice® technology allows patients to continue to live their daily lives with minimal disruption despite the advanced stage of their COPD disease.”

The Company is currently in discussions with potential partners in Europe and expects to begin marketing the LifeChoice® Technology in the region in early 2012.

– Ends –

About Inova Labs

Inova Labs is an Austin, Texas based medical device company which develops and commercializes innovative products for the COPD market.  The company is currently marketing the LifeChoice® Portable Oxygen Concentrator System, which is the lightest and smallest oxygen concentrator on the market with FDA approval for continuous use by patients.   LifeChoice® delivers oxygen to the COPD patient using a proprietary “Pulse Wave” technology, which insures that the patient receives maximum benefit from the oxygen produced.  LifeChoice® also offers “Auto Mode” technology which enables the patient to automatically receive the prescribed oxygen dose during periods of activity as well as sleep.  The product is approved by FAA for air travel and is manufactured under strict ISO certification guidelines.

Gilde Healthcare Portfolio Company Big Health Raises $75 Million in Series C Funding

Big Health, a digital therapeutics company dedicated to helping millions back to good mental health, today announced that it has raised $75 million in a Series C funding round, led by new investor SoftBank Vision...
19. Januar 2022

ProVerum raises €30M in Series A funding led by Gilde Healthcare & Lightstone Ventures

ProVerum Limited, an Irish medical device company developing a minimally invasive solution to treat benign prostatic hyperplasia (BPH) in the doctor’s office, today announced the closing of a €30 million Series A equity financing led...
11. Januar 2022

Gilde Healthcare portfolio Volta Medical treats first U.S. patients with persistent cardiac arrythmias

Volta Medical, a pioneering health tech company developing artificial intelligence (AI)-based software solutions to treat cardiac arrythmias, today announced the introduction of its leading-edge product, VX1, at three leading U.S. hospitals. New York Presbyterian Queens,...
21. Dezember 2021